Skuteczność i bezpieczeństwo terapii łączonej: walsartan z indapamidem o przedłużonym uwalnianiu Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2025
Słowa kluczowe:
nadciśnienie tętnicze, walsartan, indapamid, single-pill combination, monoterapia
##plugins.themes.bootstrap3.article.main##
Abstrakt
Zgodnie z zaleceniami Europejskiego Towarzystwa Kardiologicznego z 2024 r. leczenie nadciśnienia tętniczego powinno opierać się na terapii skojarzonej, najlepiej w formie preparatu złożonego, ponieważ poprawia to jej skuteczność i przestrzeganie zaleceń. Połączenie walsartanu (antagonisty receptora angiotensyny II) z indapamidem o przedłużonym uwalnianiu (diuretykiem tiazydopodobnym) oferuje komplementarne mechanizmy hipotensyjne przy zachowanym bezpieczeństwie terapii, korzystnym profilu metabolicznym i dodatkowym działaniu nefro- i kardioprotekcyjnym. Zostało to potwierdzone w populacjach wysokiego ryzyka – osób z chorobami sercowo-naczyniowymi i w starszym wieku. Kombinacja walsartanu z indapamidem o przedłużonym uwalnianiu to nowoczesna i skuteczna opcja terapeutyczna w nadciśnieniu tętniczym.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Skwarek, A., & Ozierański, K. (2025). Skuteczność i bezpieczeństwo terapii łączonej: walsartan z indapamidem o przedłużonym uwalnianiu. Medycyna Faktów , 18(2(67), 271-275. https://doi.org/10.24292/01.MF.0225.15
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. McEvoy JW, McCarthy CP, Bruno RM et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension: Developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO). Eur Heart J. 2024; 45(38): 3912-4018.
2. Byrne RA, Rossello X, Coughlan JJ et al. 2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2023; 44(38): 3720-826.
3. McDonagh TA, Metra M, Adamo M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021; 42(36): 3599-726.
4. Black HR, Graff A, Shute D et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Hum Hypertens. 1997; 11(8): 483-9.
5. Holwerda NJ, Fogari R, Angeli P et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens. 1996; 14(9): 1147-51.
6. Hanefeld M, Abletshauser C. Effect of the angiotensin II receptor antagonist valsartan on lipid profile and glucose metabolism in patients with hypertension. J Int Med Res. 2001; 29(4): 270-9.
7. Julius S, Weber MA, Kjeldsen SE et al. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension. 2006; 48(3): 385-91.
8. Hollenberg NK, Parving HH, Viberti G et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens. 2007; 25(9): 1921-6.
9. Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003; 349(20): 1893-906.
10. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001; 345(23): 1667-75.
11. Beckett NS, Peters R, Fletcher AE et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008; 358(18): 1887-98.
12. Emeriau JP, Knauf H, Pujadas JO et al.; European Study Investigators. A comparison of indapamide SR 1.5 mg with both amlodipine 5 mg and hydrochlorothiazide 25 mg in elderly hypertensive patients: a randomized double-blind controlled study. J Hypertens. 2001; 19(2): 343-50.
13. Ambrosioni E, Safar M, Degaute JP et al. Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide: results of randomised double-blind controlled studies. European study group. J Hypertens. 1998; 16(11): 1677-84.
14. Ames RP. A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides. Am J Cardiol. 1996; 77(6): 12b-6b.
2. Byrne RA, Rossello X, Coughlan JJ et al. 2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2023; 44(38): 3720-826.
3. McDonagh TA, Metra M, Adamo M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021; 42(36): 3599-726.
4. Black HR, Graff A, Shute D et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Hum Hypertens. 1997; 11(8): 483-9.
5. Holwerda NJ, Fogari R, Angeli P et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens. 1996; 14(9): 1147-51.
6. Hanefeld M, Abletshauser C. Effect of the angiotensin II receptor antagonist valsartan on lipid profile and glucose metabolism in patients with hypertension. J Int Med Res. 2001; 29(4): 270-9.
7. Julius S, Weber MA, Kjeldsen SE et al. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension. 2006; 48(3): 385-91.
8. Hollenberg NK, Parving HH, Viberti G et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens. 2007; 25(9): 1921-6.
9. Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003; 349(20): 1893-906.
10. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001; 345(23): 1667-75.
11. Beckett NS, Peters R, Fletcher AE et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008; 358(18): 1887-98.
12. Emeriau JP, Knauf H, Pujadas JO et al.; European Study Investigators. A comparison of indapamide SR 1.5 mg with both amlodipine 5 mg and hydrochlorothiazide 25 mg in elderly hypertensive patients: a randomized double-blind controlled study. J Hypertens. 2001; 19(2): 343-50.
13. Ambrosioni E, Safar M, Degaute JP et al. Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide: results of randomised double-blind controlled studies. European study group. J Hypertens. 1998; 16(11): 1677-84.
14. Ames RP. A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides. Am J Cardiol. 1996; 77(6): 12b-6b.